Shares of pico cap Novogen (NVGN) are up 15% premarket on modest volume in response to its announcement that it has identified a number of super-benzopyran (SBP) compounds with anti-cancer activity against human prostate cancer cells in vitro.
Retail investors need to exercise caution here because there is a colossal amount of time, money and effort ahead if the company intends to seek regulatory clearance for any of these product candidates. Novogen's market cap is only $24M and it is thinly traded (34K/day). Another red flag is the involvement of SA Contributor Biotech Breakthroughs. His promotion of Atossa Genetics (ATOS) ~1 year ago provides informative background info.